BIIB033
Jump to navigation
Jump to search
Monoclonal antibody | |
---|---|
Type | ? |
Clinical data | |
Other names | Anti-LINGO-1 |
Legal status | |
Legal status |
|
Identifiers | |
CAS Number |
BIIB033 (also known as Anti-LINGO-1) is a monoclonal antibody targeting LINGO1. As of 2015 it was being developed by Biogen as a treatment for diseases such as multiple sclerosis and optic neuritis.[1][2][3]
See also
References
- ^ "Biogen MS Drug Results Are 'Mildly Encouraging' In Eye Disease Test". Forbes. Retrieved 2015-10-13.
- ^ Clinical trial number NCT01864148 for "Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex" at ClinicalTrials.gov
- ^ Tran JQ, Rana J, Barkhof F, Melamed I, Gevorkyan H, Wattjes MP, et al. (August 2014). "Randomized phase I trials of the safety/tolerability of anti-LINGO-1 monoclonal antibody BIIB033". Neurology. 1 (2): e18. doi:10.1212/NXI.0000000000000018. PMC 4202679. PMID 25340070.
Categories:
- Articles with short description
- Short description matches Wikidata
- Drugs with non-standard legal status
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Articles containing unverified chemical infoboxes
- Drugs that are a monoclonal antibody
- Monoclonal antibodies
- Experimental drugs
- All stub articles
- Monoclonal antibody stubs